Urinary peptidomics identifies potential biomarkers for major depressive disorder

Psychiatry Research

Volumn 217, Issue 1-2, 2014, Pages 25-33

  Wang, Ying ^a,b,c   Chen, Jianjun ^b,c   Chen, Liang ^a,b,c   Zheng, Peng ^a,b,c   Xu, Hong Bo ^a,b,c   Lu, Jia ^a,b,c   Zhong, Jiaju ^a,b,c   Lei, Yang ^a,b,c   Zhou, Chanjuan ^a,b,c   Ma, Qingwei ^d   Li, Yan ^d   Xie, Peng ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING KEY LABORATORY OF NEUROBIOLOGY   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d Bioyong (Beijing) Technology Co Ltd   (China)

Author keywords

Depression; Diagnosis; Diagnostic; MDD; Peptide pattern; Urine

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; APOLIPOPROTEIN A1; PROTEOHEPARAN SULFATE; BIOLOGICAL MARKER; PEPTIDE; PROTEOME;

ADULT; ALBUMIN BLOOD LEVEL; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE MARKER; DOWN REGULATION; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; UPREGULATION; CASE CONTROL STUDY; DEPRESSIVE DISORDER, MAJOR; MASS SPECTROMETRY; PROTEOMICS; URINE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PEPTIDES; PROTEOME; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84899915560     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.02.029     Document Type: Article

References (52)

1. Allhorn M., Lundqvist K., Schmidtchen A., Akerström B. Heme-scavenging role of alpha1-microglobulin in chronic ulcers. Journal of Investigative Dermatology 2003, 121:640-646.
2. Andrews G.L., Simons B.L., Young J.B. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Analytical Chemistry 2011, 83:5442-5446.
3. Aristoteli L.P., Molloy M.P., Baker M.S. Evaluation of endogenous plasma peptide extraction methods for mass spectrometric biomarker discovery. Journal of Proteome Research 2007, 6:571-581.
4. Caines P.S., Thibert R.J., Draisey T.F., Foreback C.C., Chu J.W. Determination of non-enzymatically glycated apolipoprotein A1. Clinical Biochemistry 1989, 22:285-287.
5. Capote F.P., Sanchez J.C. Strategies for proteomic analysis of non-enzymatically glycated proteins. Mass Spectrometry Reviews 2009, 28:135-146.
6. Cho W., Jung K., Regnier F.E. Use of glycan targeting antibodies to identify cancer-associated glycoproteins inplasma of breast cancer patients. Analytical Chemistry 2008, 80:85286-85292.
7. Connor T.J., Leonard B.E. Biological markers for depression. Antidepressants. Past, Present and Future. Handbook of Experimental Pharmacology 2004, 117-148. Springer, New York. S.H. Preskorn, J.P. Feighner, C. Stanga, R. Ross (Eds.).
8. Craddock N., Forty L. Genetics of affective (mood) disorders. European Journal of Human Genetics 2006, 14:660-668.
9. Curtiss L.K., Witztum J.L. Plasma Apolipoproteins Al, All, B, Cl, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 1985, 34:452-461.
10. Decramer S., de Peredo A.G., Breuil B., Mischak H., Monsarrat B., Bascands J.L., Schanstra J.P. Urine in clinical proteomics. Molecular and Cellular Proteomics 2008, 7:1850-1862.
11. Dekker L.J., Boogerd W., Stockhammer G., Dalebout J.C., Siccama I., Zheng P., Bonfrer J.M., Verschuuren J.J., Jenster G., Verbeek M.M. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Molecular and Cellular Proteomics 2005, 4:1341-1349.
12. Domenici E., Muglia P. The search for peripheral disease markers in psychiatry by genomic and proteomic approaches. Expert Opinion on Medical Diagnostics 2007, 1:235-251.
13. Don B.R., Kaysen G. Serum lipid concentrations in patients with major depressive disorder. Seminars in Dialysis 2004, 17:432-437.
14. Emanuele E., Colombo R., Martinelli V., Brondino N., Marini M., Boso M., Barale F., Politi P. Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuro Endocrinology Letters 2010, 31:117.
15. Ezzaher A., Haj Mouhamed D., Mechri A., Neffati F., Douki W., Gaha L., Najjar M.F. Thyroid function and lipid profile in bipolar I patient. Asian Journal of Psychiatry 2011, 4:139-143.
16. Fava M., Kendler K.S. Major depressive disorder. Neuron 2000, 28:335-341.
17. Fort P.E., Freeman W.M., Losiewicz M.K., Singh R.S., Gardner T.W. The retinal proteome in experimental diabetic retinopathy: up-regulation ofcrystallins and reversal by systemic and periocular insulin. Molecular and Cellular Proteomics 2009, 8:767-779.
18. Fujii H., Saito K., Hamakawa H., Maekawa N., Fujigaki S., Wada H., Shimokawa K., Seishima M., Takami T. Immunohistochemical localization and mRNA expression of apolipoprotein A-I in rat spinal cord. Journal of Atherosclerosis and Thrombosis 2002, 9:93-98.
19. Good D.M., Wirtala M., McAlister G.C., Coon J.J. Performance characteristics of electron transfer dissociation mass spectrometry. Molecular and Cellular Proteomics 2007, 6:1942-1951.
20. Good D.M., Coon J.J. Advancing proteomics with ion/ion chemistry. BioTechniques 2006, 40:783-789.
21. Gudmundsson P., Skoog I., Waern M., Blennow K., Zetterberg H., Rosengren L., Gustafson D. Is there a CSF biomarker profile related to depression in elderly women?. Psychiatry Research 2010, 176:174-178.
22. Harr S.D., Uint L., Hollister R., Hyman B.T., Mendez A.J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer[U+05F3]s disease. Journal of Neurochemestry 1996, 66:2429-2435.
23. Henriksson M.M., Aro H.M., Marttunen M.J., Heikkinen M.E., Isometsa E., Kuoppasalmi K., Lonnqvist J. Mental disorders and comorbidity in suicide. American Journal of Psychiatry 1993, 150:935-940.
24. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clinical Chemistry 2006, 52:1223-1237.
25. Hortin G.L., Jortani S.A., Ritchie J.C., Valdes R., Chan D.W. Proteomics: a new diagnostic frontier. Clinical Chemistry 2006, 52:1218-1222.
26. Huang J.T., Wang L., Prabakaran S., Wengenroth M., Lockstone H.E., Koethe D., Gerth C.W., Gross S., Schreiber D., Lilley K., Wayland M., Oxley D., Leweke F.M., Bahn S. Independent protein-profiling studies show a decrease in apolipoprotein A1 levelsin schizophrenia CSF, brain and peripheral tissues. Molecular Psychiatry 2008, 13:1118-1128.
27. Itoh H., Ide H., Ishikawa N., Nawa Y. Mast cell protease inhibitor, trypstatin, is a fragment of inter-alpha-trypsin inhibitor light chain. Journal of Biological Chemistry 1994, 269:3818-3822.
28. Kallunki P., Tryggvason K. Human basement membrane heparan sulfate proteoglycan core protein: a 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. The Journal of Cell Biology 1992, 116:559-571.
29. Koomen J.M., Li D.H., Xiao L.C., Liu T.C., Coombes K.R., Abbruzzese J., Kobayashi R. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. Journal of Proteome Research 2005, 4:972-981.
30. Liang T., Wang N., Li W., Li A., Wang J., Cui J., Liu N., Li Y., Li L., Yang G., Du Z., Li D., He K., Wang G. Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics 2010, 10:90-98.
31. Maes M., Smith R., Christophe A., Vandoolaeghe E., Van Gastel A., Neels H., Demedts P., Wauters A., Meltzer H.Y. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatrica Scandinavica 1997, 95:212-221.
32. Maes M., Wauters A., Verkerk R., Demedts P., Neels H., Van Gastel A., Cosyns P., Scharpe S., Desnyder R. Lower serum l-tryptophan availability in depression as a marker of a moregeneralized disorder in protein metabolism. Neuropsychopharmacology 1996, 15:243-251.
33. Marc D.T., Ailts J.W., Campeau D.C.A., Bull M.J., Olson K.L. Neurotransmitters excreted in the urine as biomarkers of nervous system activity: validity and clinical applicability. Neuroscience and Biobehavioral Reviews 2011, 35:635-644.
34. Mitchell A.J., Vaze A., Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. The Lancet 2009, 374:609-619.
35. Momeni N., Bergquist J., Brudin L., Behnia F., Sivberg B., Joghataei M., Persson B. A novel blood-based biomarker for detection of autism spectrum disorders. Translational Psychiatry 2012, 2:e91.
36. Mubarak A., Gad E.I., Ibrahim W.F. Immunological study of Manic patients. German Journal of Psychiatry 1999, 2:48-60.
37. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. The Lancet 1997, 349:1498-1504.
38. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C. Use of proteomic patterns in serum to identify ovarian cancer. The Lancet 2002, 359:572-577.
39. Petricoin E.F., Belluco C., Araujo R.P., Liotta L.A. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nature Reviews Cancer 2006, 6:961-967.
40. Pio R., Martinez A., Unsworth E.J., Kowalak J.A., Bengoechea J.A., Zipfel P.F., Elsasser T.H., Cuttitta F. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both Partners. Journal of Biological Chemistry 2001, 13:12292-12300.
41. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer[U+05F3]s disease. Molecular Brain Research 2003, 118:140-146.
42. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnology 2006, 24:971-983.
43. Schmidt H.D., Shelton R.C., Duman R.S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2011, 36:2375-2394.
44. Schwamborn K., Krieg R.C., Grosse J., Reulen N., Weiskirchen R., Knuechel R., Jakse G., Henkel C. Serum proteomic profiling in patients with bladder cancer. European Urology 2009, 56:989-996.
45. Ustun T.B., Von Korff M. Primary mental health services. Mental Illness in General Health Care: An International Study 1995, 347-360. John Wiley & Sons, Chichester. T.B. Ustun, N. Sartorius (Eds.).
46. Wang P.S., Simon G., Kessler R.C. The economic burden of depression and the cost-effectiveness of treatment. International Journal of Methods in Psychiatric Research 2003, 12:22-33.
47. Watson S., Gallagher P., Smith M.S., Ferrier I.N., Young A.H. The dex/CRH test-is it better than the DST?. Psychoneuroendocrinology 2006, 31:889-894.
48. Wu J., Wang N., Wang J., Xie Y., Li Y., Liang T., Yin Z., He K., Chen X. Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Communications in Mass Spectrometry: RCM 2010, 24:1971-1978.
49. Xiao D., Meng F.L., He L.H., Gu Y.X., Zhang J.Z. Analysis of the urinary peptidome associated with Helicobacter pylori infection. World Journal of Gastroenterology: WJG 2011, 17:618-624.
50. Xu H.B., Zhang R.F., Luo D., Zhou Y., Wang Y., Fang L. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. International Journal of Neuropsychopharmacology 2012, 15:1413-1425.
51. Zheng P., Gao H.C., Li Q., Shao W.H., Zhang M.L., Cheng K., Yang D.Y., Fan S.H., Chen L., Fang L. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. Journal of Proteome Research 2012, 11:1741-1748.
52. Zürbig P., Renfrow M.B., Schiffer E., Novak J., Walden M., Wittke S., Just I., Pelzing M., Neususs C., Theodorescu D., Root C., Ross M., Mischak H. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006, 27:2111-2125.